Vertex Pharmaceuticals is buying an endocrine treatment specialist for $10 billion.
Vertex will acquire Crinetics Pharmaceuticals for $10 billion, its largest deal yet, adding an approved rare-disease drug to ...
They have at least one thing in common: An exciting pipeline.
Swiss pharmaceutical giant Novartis has agreed to buy London-based biotech Myricx Bio for up to $1.5bn (£1.1bn) as global ...
As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.
Call AI in biotech hype at your peril. There are real reasons that pharmaceutical companies are embracing this technology ...
Biotech companies are spending billions to perfect chemical formulas, only to be tripped up by the one variable they forgot ...
Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.
Candel Therapeutics (CADL) shifts to late-stage oncology with CAN-2409 Phase III wins and BLA catalyst. Read here for a ...
Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.
Parabilis Medicines, NewLimit, Enliven Therapeutics, and Kardigan bagged the biggest biotech funding rounds overall in June 2026.
Seven life sciences companies cut at least 346 jobs in Massachusetts between April and June, with some of the layoffs tied to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results